IFCR Adds Two New Centers of Excellence
The International Foundation for CDKL5 Research (IFCR) is pleased to announce the addition of two new CDKL5 Centers of Excellence in the United States – Monroe Carell Jr. Children’s Hospital at Vanderbilt located in Nashville, TN and The Children’s Hospital at Montefiore Medical Center located in Bronx, NY. The addition of these two sites brings the number of CDKL5 Centers of Excellence in the US to ten.Read More
Jesus Gonzalez Appointed Inaugural Executive Director of IFCR
We are thrilled to welcome Jesus Gonzalez to our team as Executive Director!
Since our start in 2009, the IFCR has been led by passionate and dedicated CDKL5 parent volunteers. From a small group of families to now a global community of affected patients that continues to grow, it is time for the IFCR to keep growing as well. The hiring of our first Executive Director is an exciting step!Read More
CDKL5 Alliance Membership Update
The IFCR has been proudly serving the CDKL5 community since 2009. As a nonprofit organization, we have a duty to fulfill our mission – to treat and cure CDKL5 Deficiency Disorder by funding scientific research, while helping affected individuals and their families to thrive.Read More
The Lancet Neurology Publishes Review of Clinical Features, Diagnosis and Management of CDKL5 Deficiency Disorder
Quality of life of caregivers and patients, as well as future direction of research, are discussed in detail for this rare and extremely severe disorderRead More
Gene Therapy: A Conversation With Drs Benke & Ultragenyx
Register now!Read More
Marinus Expanded Access Program for Ganaxolone
We asked Marinus to tell us more about their new Expanded Access Program (EAP) for ganaxolone.Read More
2020 IFCR Highlights
Last year at this time we were contemplating the promise that a new year brings and to say 2020 presented obstacles we couldn’t anticipate is redundant, yet we found the silver lining in opportunities lost to regroup and refocus on our mission. This year we find ourselves contemplating our future in a much different light, asking propelling questions and making tough decisions. Given the constraints that most rare disease communities face, how can we best use limited resources? How can we partner with others to realize timely progress? How can newfound opportunities in telemedicine and video-based applications afford new potential directions for rare disease communities to connect or share data with scientists?
Reflecting on past years, it is remarkable how fast science is moving. Genetic therapies are under early development for CDKL5 Deficiency Disorder. We must prepare for any future we are afforded to trial disease-modifying treatments. To be ready for clinical trials…Read More
NIH Awards Clinical Trial Readiness UO1 Grant to the International CDKL5 Clinical Research Network
“This NIH Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.”
The Co-Directors of the International CDKL5 Disorder Database (ICDD)- a rich natural history database collecting parent-reported and genetic data and the Directors of the eight IFCR-funded CDKL5 Centers of Excellence (COEs) – a network of clinics throughout the USA that specialize in the care of patients with CDKL5 Deficiency Disorder (CDD) actively participate in a collaborative research infrastructure, the International CDKL5 Clinical Research Network (ICCRN). This network was initiated through IFCR funding. The ICCRN seeks to answer clinically significant questions to drive improvements in the clinical care of patients with CDD. To date, IFCR support has led to 12 publications since 2017 fostered by this collaboration. Disease-modifying therapies are currently in development for CDD patients, but a mission-critical step remains unfilled prior to the FDA-approved initiation of clinical trials.
There are no measures validated for CDD and the severity of this condition renders those outcome measures that exist unsuitable.Read More
CDKL5 Deficiency Disorder Voice of the Patient Report Submitted to FDA
Understanding the patient voice is fundamental for therapy development. Companies need to ensure that what matters most to patients is being assessed, and regulators and payers asks for demonstration of value to support approval and reimbursement. Today, the Loulou Foundation and the International Foundation for CDKL5 Research (IFCR) are proud to release the “CDKL5 Deficiency Disorder Voice of the Patient Report”, capturing the voice of patients living with this rare genetic disease that affects thousands of people.
The report is the outcome of a groundbreaking patient-centered meeting …Read More
IFCR & RDMD Partner to Accelerate Drug Development
*RDMD is now Allstripes
You can accelerate drug development in CDKL5 (CDKL5 deficiency disorder)
Important research records are trapped in hospitals across the country. As a result, drug researchers can’t access the information they need to advance treatments.
But as a patient caregiver, you can. Unlock your records and contribute them to research, privately and securely.